The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the ...

Novo Nordisk ( NVO 5.29%) stock ran up 3.5% through 10:05 a.m. ET Friday morning on some good news for it (and for Eli Lilly ...

The shortage of Novo Nordisk’s (NVO) blockbuster weight loss drugs has been resolved, according to the U.S. Food and Drug ...

Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...

Makers of copycat versions of Novo Nordisk's (NVO) weight-loss drug semaglutide, also known as Ozempic and Wegovy, are suing ...

The Food & Drug Administration announced last week that the Ozempic and Wegovy shortage for Novo Nordisk‘s (NYSE:NVO) was ...

Compounders have filed a lawsuit against the FDA challenging its decision to remove Novo Nordisk's Wegovy and Ozempic from the shortage list. The lawsuit claims the FDA's actions are arbitrary, ...

Novo Nordisk thrives despite competition and explore its breakthrough amycretin study. Read here to know why we rate NVO ...

Compounded GLP-1s have become more widespread, but are they safe? Some argue that compounding is nothing new, while others ...

The FDA has removed semaglutide from its drug shortage list after the agency determined the current supply of the drug can ...

The Food and Drug Administration on Friday announced that semaglutide, the active ingredient in weight loss drugs Ozempic and ...